124 related articles for article (PubMed ID: 15315341)
21. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension.
Stergiou GS; Skeva II; Baibas NM; Roussias LG; Kalkana CB; Achimastos AD; Mountokalakis TD
J Cardiovasc Pharmacol; 2000 Jun; 35(6):937-41. PubMed ID: 10836730
[TBL] [Abstract][Full Text] [Related]
22. Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT1 receptors.
Chow L; De Gasparo M; Levens N
Eur J Pharmacol; 1995 Aug; 282(1-3):77-86. PubMed ID: 7498292
[TBL] [Abstract][Full Text] [Related]
23. Beneficial effect of all-trans retinoic acid (ATRA) on glomerulosclerosis rats via the down-regulation of the expression of alpha-smooth muscle actin: a comparative study between ATRA and benazepril.
Hu P; Qin YH; Pei J; Lei FY; Hu B; Lu L
Exp Mol Pathol; 2010 Aug; 89(1):51-7. PubMed ID: 20493835
[TBL] [Abstract][Full Text] [Related]
24. [Effects of rhein on activity of caspase-3 in kidney and cell apoptosis on the progression of renal injury in glomerulosclerosis].
Ji ZQ; Huang CW; Liang CJ; Sun WW; Chen B; Tang PR
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(26):1836-41. PubMed ID: 16253190
[TBL] [Abstract][Full Text] [Related]
25. Altered signaling and regulatory mechanisms of apoptosis in focal and segmental glomerulosclerosis.
Wang W; Tzanidis A; Divjak M; Thomson NM; Stein-Oakley AN
J Am Soc Nephrol; 2001 Jul; 12(7):1422-1433. PubMed ID: 11423571
[TBL] [Abstract][Full Text] [Related]
26. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone.
Waeber B; Aschwanden R; Sadecky L; Ferber P
J Hypertens; 2001 Nov; 19(11):2097-104. PubMed ID: 11677377
[TBL] [Abstract][Full Text] [Related]
27. Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats.
Webb RL; Navarrete AE; Davis S; de Gasparo M
J Hypertens; 1998 Jun; 16(6):843-52. PubMed ID: 9663925
[TBL] [Abstract][Full Text] [Related]
28. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction.
Jiang J; Tian L; Huang Y; Xie S; Xu L; Liu H; Li Y
Int J Clin Pharmacol Ther; 2011 Dec; 49(12):756-64. PubMed ID: 22122818
[TBL] [Abstract][Full Text] [Related]
30. Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress.
Yagi S; Morita T; Katayama S
Hypertens Res; 2004 Feb; 27(2):129-35. PubMed ID: 15005276
[TBL] [Abstract][Full Text] [Related]
31. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure.
Kim S; Yoshiyama M; Izumi Y; Kawano H; Kimoto M; Zhan Y; Iwao H
Circulation; 2001 Jan; 103(1):148-54. PubMed ID: 11136700
[TBL] [Abstract][Full Text] [Related]
32. Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study.
Ruggenenti P; Cortinovis M; Parvanova A; Trillini M; Iliev IP; Bossi AC; Belviso A; Aparicio MC; Trevisan R; Rota S; Perna A; Peracchi T; Rubis N; Martinetti D; Prandini S; Gaspari F; Carrara F; De Cosmo S; Tonolo G; Mangili R; Remuzzi G;
PLoS Med; 2021 Jul; 18(7):e1003691. PubMed ID: 34260595
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP.
Siragy HM; de Gasparo M; El-Kersh M; Carey RM
Hypertension; 2001 Aug; 38(2):183-6. PubMed ID: 11509473
[TBL] [Abstract][Full Text] [Related]
34. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
Jacobsen P; Andersen S; Jensen BR; Parving HH
J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
[TBL] [Abstract][Full Text] [Related]
35. [Effect of Shen-Mai injection and aminophylline on diaphragmatic muscle cell apoptosis and related gene expression in rats with chronic hypoxia].
Zhao LM; Xiong SD; Niu RJ; Xu YJ; Zhang ZX
Zhonghua Jie He He Hu Xi Za Zhi; 2003 Oct; 26(10):606-9. PubMed ID: 14633443
[TBL] [Abstract][Full Text] [Related]
36. Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury.
Bakris GL; Griffin KA; Picken MM; Bidani AK
J Hypertens; 1997 Oct; 15(10):1181-5. PubMed ID: 9350593
[TBL] [Abstract][Full Text] [Related]
37. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension.
Anan F; Takahashi N; Ooie T; Yufu K; Hara M; Nakagawa M; Yonemochi H; Saikawa T; Yoshimatsu H
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):353-9. PubMed ID: 15918057
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of anti-apoptotic action of dipfluzine on neuronal damage of the rat hippocampal CA1 region subjected to transient forebrain ischemia.
Zhang YJ; Guo Y; Jia QZ; Wang YL; Zhang HL
Yao Xue Xue Bao; 2005 Feb; 40(2):97-104. PubMed ID: 15875662
[TBL] [Abstract][Full Text] [Related]
39. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
Ohishi M; Takeya Y; Tatara Y; Yamamoto K; Onishi M; Maekawa Y; Kamide K; Rakugi H
Hypertens Res; 2010 Nov; 33(11):1150-4. PubMed ID: 20703230
[TBL] [Abstract][Full Text] [Related]
40. Mycophenolate mofetil and valsartan inhibit podocyte apoptosis in streptozotocin-induced diabetic rats.
Lv W; Zhang Y; Guan G; Li P; Wang J; Qi D
Pharmacology; 2013; 92(3-4):227-34. PubMed ID: 24158161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
